Expert Lectures Prof. Dr. N.W. Clarke
Current Hot Topics in Advanced Prostate Cancer Treatment
In view of the increasingly complex treatment landscape for prostate cancer, these and other questions arise in clinical practice:
Who benefits from early treatment intensification in advanced prostate cancer?
Who should get PARP inhibitors for the treatment of prostate cancer and at which stage?
Prof. Noel Clarke spoke about these topics in several lectures at Swiss hospitals in September 2023.
Have a look at the recordings below to learn more.
Professor Dr. Noel W Clarke
Consultant urologist surgeon at Christie Manchester and Salford Royal
United Kingdom
Find more events and webinars here
The statements of fact and opinions expressed are those of the speaker and do not necessarily reflect the opinions or position of Bayer (Schweiz) AG.
The presentations might contain information on compounds that are investigational or are being investigated for uses, that are not approved by Swissmedic or other health authorities. This information is presented only for the purpose of providing a general overview and should not be construed as recommendation for use of any product for unapproved uses.
The referenced data, resp. publications, will be made available upon request.
The above content, including any links, contains information that may be confidential or not intended for the public. It is only intended for the designated recipient(s). The use, distribution, dissemination and reproduction of this content are prohibited and may be illegal.
AS.: Darolutamide. I.: NUBEQA is indicated in comb. with androgen deprivation therapy (ADT) for the treatm. of adult pat. with metastatic hormone-sensitive prostate cancer (mHSPC). NUBEQA is indicated in comb. with docetaxel and ADT for the treatm. of adult pat. with mHSPC, for whom docetaxel therapy is indicated. NUBEQA is indicated in comb. with ADT for the treatm. of adult pat. with non-metastatic, castration-resistant prostate cancer (nmCRPC), for those who are at high risk of develop. metastases (especially with a PSA-DT ≤ 10 m.). D/A: 600 mg (two 300 mg film-coated tablets) taken 2/day with a meal (total daily dose of 1200 mg). pat. receiving NUBEQA should also receive an LHRH agonist or antagonist concurrently or have had a bilat. orchiectomy. When used in comb. with docetaxel, the 1. of 6 docetaxel cycles should begin within 6 weeks of starting NUBEQA. CI.: Hypersensitivity to the active pharmaceut. ingredient or to one of the excipients. Women who are pregnant or of childbearing potential. Spec.W./Prec.: Renal/hepatic impairment: Closely monitor pat. with severe renal impair. or moderate/severe hepatic impair. for adverse reactions. Hepatotox.: In case of liver funct. test abnormalities suggestive of idiosyncr. DILI, NUBEQA must be permanently discont. ADT can prolong the QT interval: In case of risk factors or concomitant medication that prolong the QT interval, ECG monitoring should be consid.. Contraception: Sexually active pat. must use a highly effective form of contracept.. Bone density: may be affected during treatm. with NUBEQA due to long-term testosterone suppr. Recent cardiovasc. disease: The safety of NUBEQA in pat. with a clinic. relevant cardiovasc. disease in the last 6 months has not been proven, follow current guidelines. The prescr. dose is practically “sodium free”. Do not take if you have hereditary galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption. AEs.: NUBEQA: Very common: Neutrophil count decr., AST and ALT incr., bilirubin incr., fatigue. Common: Ischaemic heart disease, cardiac failure, rash, pain in extremities, fractures. NUBEQA in comb. with docetaxel: Very common: Hypertension including occasional hypertensive emergency, AST incr., ALT incr., bilirubin incr., rash. Interactions: BCRP inhibitor, OATP 1B1 and 1B3, in the case of concurrent use with corresp. substrates, follow the recommendations in the resp. prescrib. information. Weak CYP3A4 inducer. Substrate of CYP3A4, P-gp, and BCRP. Use of strong CYP3A4 inducers and P-gp inducers during treatm. with NUBEQA should be avoided. UE: Very common: Neutrophil count decreased, AST and ALT increased, Bilirubin increased, Fatigue. Common: Ischaemic heart disease, Cardiac failure, Rash, Pain in extremities, Fractures. NUBEQA in combination with Docetaxel: Very common: Hypertension including hypertensive emergency, AST increased, ALT increased, Bilirubin increased, Rash. List: B. Bayer (Schweiz) AG, 8045 Zurich. Further inform.: www.swissmedicinfo.ch.
RP-M_DAR-CH-0108-3 07/2025
Drug substance: Radium Ra-223 dichloride. Indication: Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without known visceral metastases. Anti-androgenic treatment is to be continued to suppress the testosterone levels to castration levels in non-orchiectomized patients. Posology/Administration: 6 injections, each of 55 kBq per kg body weight, given at 4-week intervals. There is no indication for use in children, adolescents and in women. Xofigo is a therapeutic radiopharmaceutical. Only to be used by authorized personnel with a corresponding license issued by the Federal Office of Public Health. Contraindications: Combination with abiraterone acetate plus prednisone/prednisolone. Pregnancy, women of child-bearing age, during lactation. Special warnings and precautions for use: Adherence to the interval given in the Information for Professionals is recommended for sequential use of abiraterone acetate plus prednisone/prednisolone and Xofigo (or inverse sequence). There are no data on the treatment of patients with asymptomatic bone metastases and is therefore not recommended. Bone marrow suppression, a hematological examination must be carried out before starting treatment and prior to every further dose. Not investigated in patients with Crohn’s disease or ulcerative colitis. In cases of spinal cord compression, standard treatment should be completed in accordance with the clinical indication before starting or resuming treatment with Xofigo. Bone fractures must be treated using orthopedic stabilization before starting or resuming treatment with Xofigo. Potential adverse effects on testicles and sperm, reliable contraception required. Contains sodium. Undesirable effects: Very common: thrombocytopenia, diarrhea, vomiting, nausea. Common: neutropenia, pancytopenia, leukopenia, injection site reactions. Uncommon: lymphopenia Interactions: The safety and efficacy of a combination therapy with Xofigo plus chemotherapy have not been investigated, effects on bone marrow suppression may be additive. Pack sizes: 1 vial containing 6 mL solution with 6600 kBq. Dispensing category A Marketing authorization holder: Bayer (Schweiz) AG, Uetlibergstrasse 132, 8045 Zurich.
Detailed Information at www.swissmedicinfo.ch.
RP-XOF-CH-0012-2 09/2021
PP-NUB-CH-0247-2 0124
